Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 01, 2019 16:30 ET | Source: Eidos Therapeutics, Inc.

Eidos Therapeutics Reports Second Quarter 2019 Financial Results

SAN FRANCISCO, Aug. 01, 2019 (GLOBE NEWSWIRE) -- Eidos Therapeutics, Inc. (Eidos) (Nasdaq: EIDX), today reported its financial results for the second quarter ended June 30, 2019 and provided an...
June 18, 2019 08:00 ET | Source: Eidos Therapeutics, Inc.

Eidos Therapeutics to Present at the 2019 BMO Prescriptions for Success Healthcare Conference

SAN FRANCISCO, June 18, 2019 (GLOBE NEWSWIRE) -- Eidos Therapeutics, Inc. (Eidos) (Nasdaq:EIDX) today announced that management will participate in a fireside chat at the 2019 BMO Prescriptions for...
May 07, 2019 16:30 ET | Source: Eidos Therapeutics, Inc.

Eidos Therapeutics Reports First Quarter 2019 Financial Results

SAN FRANCISCO, May 07, 2019 (GLOBE NEWSWIRE) -- Eidos Therapeutics, Inc. (Eidos) (Nasdaq:EIDX), today reported its financial results for the first quarter ended March 31, 2019 and provided an...
April 19, 2019 08:00 ET | Source: Eidos Therapeutics, Inc.

Eidos Therapeutics to Present at Two Upcoming Investor Conferences

SAN FRANCISCO, April 19, 2019 (GLOBE NEWSWIRE) -- Eidos Therapeutics, Inc. (Eidos) (Nasdaq:EIDX) today announced that management will present at two upcoming investor conferences. Class of 2018...
April 15, 2019 08:30 ET | Source: Eidos Therapeutics, Inc.

Eidos Therapeutics Reports Fourth Quarter and Year-End 2018 Financial Results

SAN FRANCISCO, April 15, 2019 (GLOBE NEWSWIRE) -- Eidos Therapeutics, Inc. (Eidos) (Nasdaq:EIDX), today reported its financial results for the fourth quarter and full year ended December 31, 2018...
March 18, 2019 09:30 ET | Source: Eidos Therapeutics, Inc.

Eidos Therapeutics Announces Publication in the Journal of the American College of Cardiology (JACC) and Presentation at American College of Cardiology (ACC) Scientific Sessions

AG10 demonstrated equivalent, near-complete stabilization of TTR in wild-type and mutant subjects with TTR amyloid cardiomyopathy (ATTR-CM). AG10 treatment normalized serum TTR levels, a prognostic...
March 11, 2019 08:00 ET | Source: Eidos Therapeutics, Inc.

Eidos Therapeutics to Present at 31st Annual ROTH Conference

SAN FRANCISCO, March 11, 2019 (GLOBE NEWSWIRE) -- Eidos Therapeutics, Inc. (Eidos) (Nasdaq:EIDX) today announced that management is scheduled to participate in a fireside chat regarding Eidos at the...
February 27, 2019 07:00 ET | Source: Eidos Therapeutics, Inc.

Eidos Therapeutics Initiates ATTRibute-CM, a Phase 3 Study of AG10 in ATTR-CM with Registrational 12-month Endpoint

ATTRibute-CM study design, which incorporates feedback from the FDA, has the potential to accelerate registration with a 12-month primary endpoint of change in 6-minute walk distance (6MWD), followed...
February 25, 2019 08:00 ET | Source: Eidos Therapeutics, Inc.

Eidos Therapeutics to Host Conference Call and Webcast to Discuss ATTR-CM Phase 3 Trial (ATTRibute-CM) Design

SAN FRANCISCO, Feb. 25, 2019 (GLOBE NEWSWIRE) -- Eidos Therapeutics, Inc. (Eidos) (Nasdaq:EIDX), a clinical stage biopharmaceutical company focused on addressing the large and growing unmet need...
February 21, 2019 08:00 ET | Source: Eidos Therapeutics, Inc.

Eidos Therapeutics to Present at Two Upcoming Investor Conferences

SAN FRANCISCO, Feb. 21, 2019 (GLOBE NEWSWIRE) -- Eidos Therapeutics, Inc. (Eidos) (Nasdaq:EIDX) today announced that management will present at two upcoming investor conferences. SVB Leerink Global...